Drugs / sc-rAAV2.5IL-1Ra
sc-rAAV2.5IL-1Ra
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02790723 | Jun 2019 → Mar 2022 | osteoarthritis, knee | Mayo Clinic | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sc-rAAV2.5IL-1Ra | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02790723 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “an in vivo gene delivery system based on adeno-associated virus (AAV) with osteoarthritis (OA) as the target disease” PMID 41607103 ↗ Feb 2026 |
| Route | Other | “delivered by intra-articular injection into one knee joint” NCT02790723 ↗ |